Chia Tai Enterprises International (CAIHF) AI Stock Analysis

Chia Tai Enterprises International

(Other OTC:CAIHF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue reboundThe sharp 2025 revenue rebound indicates a meaningful recovery in business activity and expands the scale from which Chia Tai can generate earnings. If sustained, greater revenue should support operating leverage, broader reinvestment capacity, and stronger competitive positioning across its animal-health and agribusiness activities.

Negative Factors

Gross margin compressionGross margin remains materially below earlier levels, indicating that pricing, product mix, or cost pressures have reduced the profitability of core activity. Unless margins recover, the company may need substantially more revenue to produce comparable earnings and could have less flexibility to absorb cost increases.

Chia Tai Enterprises International (CAIHF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $270.48M
Dividend Yield: ―
Average Volume (3M): 240
Price to Earnings (P/E): 10.3
Beta (1Y): 9.73
Revenue Growth: -18.95%
EPS Growth: -6.95%
Country: US
Employees: 1,000
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Chia Tai Enterprises International Business Overview & Revenue Model

Company Description

Chia Tai Enterprises International Limited primarily produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operati...

Chia Tai Enterprises International Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CAIHF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:0950	68Neutral	HKD 606.50M	3.64	8.02%	5.61%	7.05%	22.46%
HK:0897	59Neutral	HKD 401.18M	100.00	0.34%	―	-8.30%	-44.44%
HK:3933	58Neutral	HKD 13.46B	20.80	3.12%	4.38%	-12.86%	-83.10%
HK:0512	54Neutral	HKD 15.30B	13.45	6.61%	3.92%	7.35%	-45.49%
HK:0570	53Neutral	HKD 5.89B	-4.80	-4.98%	0.30%	-15.80%	-298.94%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CAIHF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CAIHF	Chia Tai Enterprises International	1.00	0.72	256.07%
HK:3933	The United Laboratories International	6.83	-5.69	-45.46%
HK:0570	China Traditional Chinese Medicine Holdings Co	1.17	-1.16	-49.79%
HK:0897	Wai Yuen Tong Medicine Holdings Limited	0.36	-0.10	-21.74%
HK:0950	Lee's Pharmaceutical Holdings Limited	1.03	-0.77	-42.94%
HK:0512	Grand Pharmaceutical Group Limited	4.31	-4.18	-49.26%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Chia Tai Enterprises International AI Stock Analysis